Constitutively active, N-terminally truncated and standard therapy resistant ErbB2/HER2 induces invasion of breast cancer cells through its downstream signalling network, which upon activation lead to the phosphorylation and activation of MZF1 at Ser 27. The gene discussed is ERBB2; the disease is breast carcinoma.